Genprex (GNPX) Total Non-Current Liabilities (2024 - 2026)
Genprex (GNPX) posted quarterly Total Non-Current Liabilities of $3.4 million for Q1 2026, up 54.21% quarter-over-quarter from $2.2 million in Q4 2025.
Genprex (GNPX) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends
Genprex's Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $3.4 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $3.4 million (changed N/A YoY), while the FY2025 annual figure was $2.2 million, down 13.16% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $3.4 million, up from $2.2 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $3.4 million in Q1 2026, with the low at $2.2 million in Q4 2025.
- The 3-year median for Total Non-Current Liabilities is $2.5 million (2024), against an average of $2.6 million.
- Peak annual rise in Total Non-Current Liabilities reached 13.16% in 2025, while the deepest fall reached 13.16% in 2025.
- Genprex's Total Non-Current Liabilities stood at $2.5 million in 2024, then dropped by 13.16% to $2.2 million in 2025, then jumped by 54.21% to $3.4 million in 2026.
- Business Quant data shows GNPX's Total Non-Current Liabilities at $3.4 million in Q1 2026, $2.2 million in Q4 2025, and $2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 9.32 Bn |
| 10 | Genprex | 1.88 Mn | -13.27 Mn | - | 2.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.35 Mn |
| Dec 31, 2025 | 2.17 Mn |
| Sep 30, 2025 | 2.55 Mn |
| Dec 31, 2024 | 2.50 Mn |